T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity
Overview
This study evaluates PRAME-specific TCR-Ts co-expressing a chimeric PD1-41BB receptor. These cells showed enhanced cytotoxicity against PRAME+ tumors in vitro and in vivo. G-Rex® were used for the 10-day expansion phase of T-cells after transduction.
What this paper found
Medigene investigators isolated a high-affinity, HLA-A2-restricted T-cell receptor against the cancer/testis antigen PRAME (TCR-027-004) from non-tolerized repertoires of healthy donors and co-expressed it in CD8+ T-cells with a chimeric PD1-41BB receptor that joins the PD-1 extracellular region to the 4-1BB signaling domain. T-cells were transduced twice retrovirally, then expanded for 10 days in G-Rex® flasks with IL-7 and IL-15 at 5 ng/mL twice weekly. Adding PD1-41BB increased IFN-γ release against PD-L1-positive tumor lines and preserved killing of 3D spheroids re-challenged on days 3, 7, 10 and 13 over 16 days, without altering functional avidity or healthy-cell recognition. In MelA375_PD-L1 xenografts, one dose of 10 million TCR-positive cells left five of seven mice without measurable tumor.
Note: The in vivo result comes from immunodeficient xenograft mice that received no supplementary human cytokines, so the activity reflects the transferred T-cells alone; no patients were treated in this study.
Remarkably, TCR-Ts co-expressing PD1-41BB were able to mediate complete tumor rejection. — Nadja Sailer, Ina Fetzer, Melanie Salvermoser, Monika Braun, Doris Brechtefeld, Christian Krendl, Christiane Geiger, Kathrin Mutze, Elfriede Noessner, Dolores J. Schendel, Maja Bürdek, Susanne Wilde, Daniel Sommermeyer, Cancers
Study details
- Authors
- Nadja Sailer, Ina Fetzer, Melanie Salvermoser, Monika Braun, Doris Brechtefeld, Christian Krendl, Christiane Geiger, Kathrin Mutze, Elfriede Noessner, Dolores J. Schendel, Maja Bürdek, Susanne Wilde, Daniel Sommermeyer
- Institution
- Medigene Immunotherapies GmbH, Planegg, Germany · Immunoanalytics-Research Group Tissue Control of Immunocytes (TCI), Helmholtz Zentrum München, Munich, Germany · Medigene AG, Planegg, Germany
- Journal
- Cancers
- Year
- 2022
- Cell type(s)
- TCR T Cells
- Application area
- Solid tumor
- Study phase
- Preclinical
How G-Rex® was used
CD8+ T cells were transduced twice in Retronectin-coated 24-well plates (0.25–0.5 × 10^6 cells per well) and, 18 to 24 hours later, moved to G-Rex® flasks (Wilson Wolf) for a 10-day expansion. During that phase fresh IL-7 and IL-15 were added twice a week at 5 ng/mL each. The cells were then harvested from the G-Rex® flasks, checked for transduction rate and frozen.
Explore related
Full citation
Sailer N, Fetzer I, Salvermoser M, et al. T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity. Cancers (Basel). 2022;14(8):1998.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.